Newsletter
November 19, 2020
ANVISA decides that a patent application related to pharmaceutical use of cannabinoids is not to be deemed as against public health
On November 17th, 2020, ANVISA’s Board of Directors (BoD) unanimously granted an administrative appeal for reassessment of prior consent of a patent application for an invention covering several cannabinoids (including THC) for pain treatment. The BoD considered that mere use of cannabinoids within the invention is not to be deemed as a threat to public health.
ANVISA’s BoD unanimously granted the administrative appeal and ordered COOPI to reassess the case. Rapporteur Director Antonio Barra Torres understood that denying prior consent only because an invention comprises the use of cannabinoids disregards relevant legal and sanitary aspects that should be taken into account. Director Alessandra Bastos Soares also noted that ANVISA’s Intellectual Property Coordination Office (COOPI) must take note of what has been decided by BoD on the subject, which is of great importance.
For further information, access here our full newsletter.
Last related news
April 28, 2022
Have you heard about the Web 3.0?
Web 3.0 is the new global trend that will impact modern society and the way people relate to the internet. It refers … Have you heard about the Web 3.0?
March 28, 2022
Brazilian PTOs publishes a technical note providing guidance on the patentability of elite events
On March 17, 2022, the BPTO released the INPI/CPAPD technical note No. 01/2022, which provides guidance on the patentability of inventions involving … Brazilian PTOs publishes a technical note providing guidance on the patentability of elite events
February 11, 2022
Data Protection becomes a fundamental right in Brazil
Yesterday (Feb. 10, 2022), the Brazilian Senate approved the Constitutional Amendment no. 115/2022, originated in the Proposal for Constitutional Amendment no. 17/2019, … Data Protection becomes a fundamental right in Brazil